Saudi Arabia's National Biotechnology Strategy, launched in January 2024, set broad national targets: $34.6 billion in non-oil GDP by 2040 and 11,000 jobs by 2030. For drug developers, the more relevant question is whether the country is answering practical questions about trials, manufacturing, capital, and talent. Recent announcements suggest it is beginning to.
At the Riyadh Global Medical Biotechnology Summit in September, research institutions and companies announced collaborations spanning genomics, proteomics, and clinical trials. King Abdullah International Medical Research Center agreed to build a Center of Excellence with Thermo Fisher Scientific and signed research pacts with Olink, Tiziana Life Sciences, and Chiyoda Corporation. A separate partnership with AstraZeneca, first signed in 2023, is now presented as a joint lab for rare disease drug discovery. On the manufacturing side, Vaccine Industrial Company said its human vaccine facility in Sudair Industrial City is 85% complete, with plans to localize up to 80% of the Kingdom's essential vaccine needs.
Capital and regulation are also becoming more concrete. The Life Sciences Innovation Forum drew applications from more than 100 companies, nominated over 25 for investment, and engaged five funds with a combined willingness to invest over $120 million—though that figure represents interest, not closed deals. The Saudi Food and Drug Authority reported an 83% increase in applications for clinical trials involving advanced therapies and biotech products in 2025, and its Reliance Pathway cut study approval times by 74% compared with the standard track.
Talent programs are addressing a key constraint for any new biomanufacturing site. Princess Nourah bint Abdulrahman University and Cellenkos launched a cell and gene therapy training program for Saudi women, while SVAX and Batterjee Medical College agreed accredited biomanufacturing training with up to 350 seats per cycle. The summit produced more than 40 agreements with a combined declared value exceeding $1.33 billion. The next test is whether these named partners and announced projects convert into measurable outcomes. (This article is based on a sponsored post from the Riyadh Global Medical Biotechnology Summit.)